Bio-techne Corp · NASDAQ:TECH

Bio-techne — Investor Presentation (May 2020)

13 slides from Bio-techne's investor presentation, May 2020

Slide 2: Cautionary Statements
SA F E H A R B O R Cautionary Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws. Except for historical information contained herein, the statements in this presentation are forward-looking and made pursuant to the safe harbor provisi
Slide 3: Business Overview
ANTIBODIES PROTEINS BUSINESS 10% 5% 3% OVERVIEW INSTRUMENTS SERVICES R OYA LT I E S PRESIDENT AND CEO Chuck Kummeth AUTOMATED HEADQUARTERS PROTEIN ANALYSIS IMMUNOASSAYS Minneapolis, MN NUMBER OF EMPLOYEES ~2,235 WORLDWIDE PRESENCE TISSUE BIOPSY LIQUID BIOPSY 35 Locations FY2019 REVENUES $714M NASDAQ
Slide 4: FY19 Revenue by Customer Type & Geography
F Y 1 9 R E V E N U E BY C U STO M E R T Y P E & G EO G R A P H Y $714M 23% 15% OEM 15% ASIA DISTRIBUTORS 25% 28% 57% ACADEMIA EMEA AMERICAS 37% PHARMA/BIOTECH © 2020 Bio-Techne®. All rights reserved. 4
Slide 6: Our Segment Structure
O U R S EG M E N T ST R U C T U R E PROTEIN SCIENCES SEGMENT DIAGNOSTICS & GENOMICS SEGMENT REAGENT A N A LY I C A L DIAGNOSTICS GENOMICS Develops and manufactures controls, Advanced, tissue morphology friendly SOLUTIONS SOLUTIONS calibrators and diagnostic assays for RNA IN SITU hybridization (ISH)
Slide 7: Bio-Techne COVID-19 Related Activities
BIO-TECHNE COVID-19 RELATED ACTIVITIES 1. RECOMBINANT COVID-19 VIRAL PROTEINS EXPRESSION: a) Virus Spike Proteins (S1, S2 & RBD) b) Virus Nucleocapsid protein c) Activating cell protease that facilitates viral entry into cells (TMPRSS2) 2. ANTIBODIES TO VIRAL PROTEINS & SMALL MOLECULE INHIBITORS: a)
Slide 8: Key Growth Platforms
K E Y G ROW T H P L AT FO R M S TISSUE BIOPSY LIQUID BIOPSY SYNERGIES CORE PRODUCTS: • ANTIBODIES • PROTEINS • I M M U N O A S S AY C E L L C U LT U R E & • C A L I B R AT O R S & INSTRUMENTS – PROTEIN GENE THERAPY CONTROLS A N A LY S I S • SMALL MOLECULES LEVERAGE CORE CONTENT © 2020 Bio-Techne®. A
Slide 9: Liquid Biopsies: The ExoDx Prostate Test
LIQUID BIOPSIES: T H E E X O D X P R O S TAT E T E S T THE WORKFLOW: URINE PAT E N T E D QRT-PCR M U LT I VA R I AT E R E S U LT: SAMPLE EXOSOMAL RNA A N A LY S I S ALGORITHMIC EXTRACTION A N A LY S I S An increasing EPI score correlates with greater risk of Algorithm high grade prostate cancer (HGP
Slide 11: End Market Breakdown
E N D M A R K E T B R EA K D OW N MARKET BIO-TECHNE BIO-TECHNE END MARKETS MARKET SIZE GROWTH GROWTH MARKET R AT E R AT E P E N E T R AT I O N PROTEOMIC RESEARCH $ 2B MID-SINGLE 7 % -8 % 15% REAGENTS DIGIT P R O T E I N A N A LY T I C A L $ 2B MID-SINGLE 15%-20% 10% TOOLS DIGIT $ 1B- $ 4B >20% C E L
Slide 12: As We Look Forward, Our Financial Goals Get Larger
A S W E LO O K FO RWA R D, O U R F I N A N C I A L G OA L S G E T L A RG E R ~$1.2B REVENUE A D J . O P E R AT I N G ~$0.5B INCOME $714M $244M $499M $198M $169M $311M ~40% FY13 FY16 FY19 FY23 FY13 FY16 FY19 FY23 Rev CAGR OM% • Analytical Solutions +15–20% • Analytical Solutions ~30% • Reagent Soluti

Bio-Techne — Investor Presentation (May 2020) on 6ix

Bio-techne — Investor Presentation (May 2020)

Slide 1: Where Science Intersects Innovation

Slide 2: Cautionary Statements

Slide 3: Business Overview

Slide 4: FY19 Revenue by Customer Type & Geography

Slide 5: Historical Organic Growth

Slide 6: Our Segment Structure

Slide 7: Bio-Techne COVID-19 Related Activities

Slide 8: Key Growth Platforms

Slide 9: Liquid Biopsies: The ExoDx Prostate Test

Slide 10: Immune Cell Therapy Opportunities

Slide 11: End Market Breakdown

Slide 12: As We Look Forward, Our Financial Goals Get Larger

Slide 13: Thank You